查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
NPS+(美国)- 前列腺癌症
市场调查报告书
商品编码
1803887

NPS+(美国)- 前列腺癌症

NPS+ (US) - Prostate Cancer
出版日期: | 出版商: FirstWord Group | 英文 | 商品交期: 最快1-2个工作天内

价格
简介目录

本报告探讨了美国肿瘤学家对前列腺癌治疗的看法，并对领先疗法的品牌忠诚度、满意度和市场占有率进行了深入分析。报告探讨了影响医生处方决策的因素、领先品牌的比较表现以及最能引起临床医生共鸣的讯息。

透过净推荐值 (NPS+) 指标和定性回馈，本报告提供了关于品牌健康状况、满意度驱动因素以及易受品牌转换影响的领域的可行洞察，从而支持医药专业人士的策略决策。

主要的问题

  • 1.比较不同品牌的 NPS 得分
  • 2.医师对特定品牌的忠诚度如何？
  • 3.哪些品牌讯息能引起医师的共鸣？
  • 4.影响医师选择的关键因素有哪些？
  • 5.主要品牌的市占率是多少？
  • 6.各主要品牌与其竞争对手相比如何？
  • 7.由于品牌满意度低，哪些品牌最有可能被消费者取代？

领导品牌

  • Aquiga
  • Lynparza
  • Nubeqa
  • Orgovix
  • Pluvicto
  • Rubraca
  • Talzenna
  • Xofigo
  • Xtandi

调查手法:

FirstView 报告是基于透过 LiMATM 选定的医生进行的定量调查而得出。 LiMATM 是全球最大的医生名录，拥有超过 300 万名医生。每位医生均根据严格的筛选标准精心挑选，以确保收集到的见解具有相关性和可靠性，反映顶尖医疗专业人士的真实意见和经验。调查结果以易于理解的图表形式呈现，方便您快速理解和分析数据。凭藉 LiMATM 的广泛覆盖范围和准确性，FirstView 报告可提供无与伦比的数据驱动洞察，指导策略规划，并帮助您在快速发展的医疗保健领域保持领先地位。

我们的报告有何独特之处？

FirstWord Reports 是值得信赖的行业领导者，专注于製药领域，为生物製药专业人士和决策者提供深入可行的洞察。我们深厚的行业知识使我们能够提供相关且有价值的洞察，帮助客户了解新兴趋势并有效应对复杂挑战。凭藉广泛的研究以及来自领先专家和关键意见领袖 (KOL) 的独立、公正的见解，我们的报告能够提供您所需的准确性和可靠性。独家访谈和数据，以及持续的市场监测，确保您能够全面了解市场动态。我们的报告涵盖 40 多个活跃的疾病领域，并提供医生情报，包括关键意见领袖洞察和定量医生调查，以及行业专家对医疗事务、数位健康、销售和营销、市场准入等领域问题的看法，使您能够做出更明智的数据驱动决策，并在快速变化的行业中保持竞争力。

简介目录

This report examines US oncologists' perspectives on prostate cancer therapies, providing a detailed analysis of brand loyalty, satisfaction, and market share among leading treatments. It explores the factors influencing physician prescribing decisions, the comparative performance of major brands, and the messages that resonate most with clinicians.

Through Net Promoter Score (NPS+) metrics and qualitative feedback, the report offers actionable insights into brand health, drivers of satisfaction, and areas where brands may be vulnerable to switching, supporting pharmaceutical professionals in strategic decision-making.

Key Questions Answered:

  • 1. How do NPS scores by brand compare?
  • 2. How loyal are physicians to specific brands?
  • 3. What brand messages resonate with physicians?
  • 4. What are the key factors driving physician choice?
  • 5. What is the market share of leading brands?
  • 6. How does each of the leading brands compare to its competitors?
  • 7. Which brands are vulnerable to switching due to low brand satisfaction?

Key Brands:

  • Akeega (abiraterone acetate/niraparib)
  • Lynparza (olaparib)
  • Nubeqa (darolutamide)
  • Orgovyx (relugolix)
  • Pluvicto
    (lutetium-177 vipivotide tetraxetan)
  • Rubraca (rucaparib)
  • Talzenna (talazoparib)
  • Xofigo (radium-223 chloride
  • Xtandi (enzalutamide)

Methodology:

FirstView reports are developed from quantitative surveys conducted with physicians selected through LiMATM, the world's largest physician directory, containing over 3 million vetted and verified physicians. Each physician is carefully chosen based on strict screening criteria to ensure the insights gathered are both relevant and reliable, reflecting the true sentiments and experiences of leading medical professionals. The findings are presented in a series of easy-to-interpret charts, enabling you to quickly grasp and analyze the data. By leveraging the vast reach and precision of LiMATM, FirstView Reports provide unparalleled, data-driven insights to guide your strategic planning and help you stay ahead in a fast-evolving healthcare landscape.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.